CHU Nimes
Nîmes, Gard, 30029, France
Location status: Recruiting
Recruiting
NCT Number: NCT04947618
Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
Observation of a cohort of 400 patients with different types of lymphomas.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Lymphoma, Malignant
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemic and Lymphatic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Plasma Cell
Paraproteinemias
Vascular Diseases
Waldenstrom Macroglobulinemia
Age range
15 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
A database on 400 patients diagnosed with lymphomas was built up over 20 years at Nîmes University Hospital. Biopsies were made on these tumours and all the samples were frozen.
Considering the heterogeneous nature of lymphomas, randomized clinical trials based on very precise criteria for the inclusion or non-inclusion of patients are the gold standard for studying the various sub-types of lymphomas by concentrating on homogeneous populations for which a limited number of parameters are analyzed simultaneously. However, due to the complexity of their medical situation, many patients may be excluded form these trials, thus making it difficult to obtain reliable results.
The analysis of a non-selected cohort has two main advantages: (1) to better understand the diversity of patients with lymphomas for which the recommendations are constantly evolving and (2) to analyze how, exactly, these are managed by integrating points which are currently poorly evaluated such as comorbidities and accessibility to treatment.
The aim of the study is to describe how these patients are managed and to demonstrate that not all patients are able to benefit from the official management recommendations applicable to their pathology.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients over the age of 15 years and 3 months, diagnosed with lymphoma at Nîmes University Hospital as from 1999 onwards and for whom diagnostic tumor material is available.
Exclusion criteria
- Patients aged 18 or over who have expressed their desire not to take part in the study.
- Patients under the age of 18 whose legal representatives have expressed their desire for the child not to take part in the study.
- Patients under legal guardianship.
Treatment and study plan
Primary outcomes
-
Overall survival rate among patients with Hodgkin Lymphomas
Time frame: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
-
Overall survival rate among patients with Mantle-cell Lymphomas
Time frame: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted.If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
-
Overall survival rate among patients with Primitive Cerebral Lymphomas
Time frame: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
-
Overall survival rate among patients with Follicular Lymphomas
Time frame: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
-
Overall survival rate among patients with Marginal Zone Lymphomas
Time frame: 2 years after inclusion
The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
-
Overall survival rate among patients with Waldenström's Disease
Time frame: 2 years after inclusion
If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted.
Secondary outcomes
-
Differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.
Time frame: 2 years after inclusion
The actual management of these patients will be compared with the data in the literature and any differences will be noted.
-
Differences between management of patients with Mantle-cell Lymphomas and data described in the literature.
Time frame: 2 years after inclusion
The actual management of these patients will be compared with the data in the literature and any differences will be noted.
-
Differences between management of patients with Primitive Cerebral Lymphomas and data described in the literature.
Time frame: 2 years after inclusion
The actual management of these patients will be compared with the data in the literature and any differences will be noted.
-
Differences between management of patients with Follicular Lymphomas and data described in the literature.
Time frame: 2 years after inclusion
The actual management of these patients will be compared with the data in the literature and any differences will be noted.
-
Differences between management of patients with Marginal Zone Lymphomas and data described in the literature.
Time frame: 2 years after inclusion
The actual management of these patients will be compared with the data in the literature and any differences will be noted.
-
Differences between management of patients with Waldenström's Disease and data described in the literature.
Time frame: 2 years after inclusion
The actual management of these patients will be compared with the data in the literature and any differences will be noted.
-
Reasons for differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.
Time frame: 2 years after inclusion
The reasons for any differences noted will be analyzed
-
Reasons for differences between management of patients with Mantle-cell Lymphomas actually observed and data described in the literature.
Time frame: 2 years after inclusion
The reasons for any differences noted will be analyzed
-
Reasons for differences between management of patients with Primitive Cerebral Lymphomas actually observed and data described in the literature.
Time frame: 2 years after inclusion
The reasons for any differences noted will be analyzed
-
Reasons for differences between management of patients with Follicular Lymphomas actually observed and data described in the literature.
Time frame: 2 years after inclusion
The reasons for any differences noted will be analyzed
-
Reasons for differences between management of patients with Marginal Zone Lymphomas actually observed and data described in the literature.
Time frame: 2 years after inclusion
The reasons for any differences noted will be analyzed
-
Reasons for differences between management of patients with Waldenström's Disease actually observed and data described in the literature.
Time frame: 2 years after inclusion
The reasons for any differences noted will be analyzed
-
Analysis of the efficacy of treatment of patients with Hodgkin Lymphomas.
Time frame: 2 years after inclusion
The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
-
Analysis of the efficacy of treatment of patients with Mantle-cell Lymphomas
Time frame: 2 years after inclusion
The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
-
Analysis of the efficacy of treatment of patients with Primitive Cerebral Lymphomas
Time frame: 2 years after inclusion
The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
-
Analysis of the efficacy of treatment of patients with Follicular Lymphomas
Time frame: 2 years after inclusion
The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
-
Analysis of the efficacy of treatment of patients with Marginal Zone Lymphomas
Time frame: 2 years after inclusion
The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
-
Analysis of the efficacy of treatment of patients with Waldenström's Disease
Time frame: 2 years after inclusion
The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis.
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Centre Hospitalier Universitaire de Nīmes
Other
Registry information
Official study title
Evaluation of the Efficacy of Management of Patients With Lymphomas Diagnosed at Nimes University Hospital Over 20 Years (1999-2018) Under Real-life Circumstances
Acronym: DVR-Lym-Nim
Important dates
- Study start
- 2024
- Primary completion
- 2027
- Study completion
- 2027
- First posted
- Jul 1, 2021
- Registry last updated
- Jun 17, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Completed
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
NCT02916979
Blood Protein Disorders, Bone Marrow Diseases
Lebanon, New Hampshire, United States
View Trial Details
Completed
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood
NCT00146055
Blood Protein Disorders, Bone Marrow Diseases
Ann Arbor, Michigan, United States
View Trial Details
Active, Not Recruiting
DS-3201b in Participants With Lymphomas
NCT02732275
Hematologic Diseases, Hemic and Lymphatic Diseases
Duarte, California, United States
View Trial Details
Completed
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
NCT00619879
Bone Marrow Diseases, Chronic Disease
Chicago, Illinois, United States
View Trial Details